

## Effects of $\Delta$ -5 and $\Delta$ -4 Androgens on the Brain

a report by

Nicola Pluchino, MD<sup>1</sup> and Andrea Riccardo Genazzani, MD, PhD, FRCOG<sup>2</sup>

1. Gynecologist; 2. Professor and Director, Department of Reproductive Medicine and Child Development, Department of Obstetrics and Gynecology, University of Pisa

DOI: 10.17925/USE.2008.04.2.118

The growth, differentiation, normal physiology, and aging of the central nervous system (CNS) are all now recognized to be influenced by gonadal steroid hormones. Steroids arriving from the gonads via the circulation modulate the responses of the brain, affecting not only sex behavior and sexually differentiated stereotypical behavioral responses, but also the ability of the brain to process, store, and retrieve sensory information.

Although much attention has been given to the study of post-menopause and the options in hormone replacement treatment (i.e. estrogens and progestins), relatively little attention and awareness has been focused on the activity of endogenous or exogenous androgens in women. In fact, the life of a middle-aged woman is characterized by the co-existence of menopause and adrenopause, which sometimes participate to create the androgen-deficiency syndrome. Thus, much more interest has been given to the study of androgen roles in the modulation of brain function in terms of sexuality, mood, cognition, and the neuroaging process. This article will focus on the neuroactive effect of androgens with particular regard to the  $\Delta$ -4 and  $\Delta$ -5 androgens.

### Androgen Level, Menopause, and the Aging Process

Several studies have investigated the effect of menopausal transition on androgen synthesis and their circulating levels. A significant reduction in testosterone (T) circulating levels occurs in pre-menopausal women. In

fact, circulating T levels in women in their 40s are 50% less than of those of women in their 20s.<sup>1</sup> Concerning post-menopause, this level has been reported as both changed and unchanged. Some studies report a small but significant decrease in T, androstenedione (A), and sex-hormone-binding globulin (SHBG) levels in the first six months after menopause.<sup>2,3</sup> However, after spontaneous menopause the ratio of T/SHBG did not show any change<sup>3,4</sup> even though in surgical menopause both T and A decrease (by about 50%), suggesting an important role of the ovaries in T secretion after menopause. On the other hand, in post-menopause the principal source of circulating T is the peripheral conversion of A and dehydroepiandrosterone (DHEA).<sup>5</sup>

From 30 years of age, circulating  $\Delta$ -5 androgens fall linearly with age independently of menopausal transition. After 70 years of age, DHEA(S) levels are 20% or less of the maximum plasma concentrations, while cortisol levels remain unchanged. In fact, it has been hypothesized that during the aging process the reduction of 17,20 desmolase activity, the enzyme that rules the biosynthesis of the  $\Delta$ -5 adrenal pathway, may induce modifications in DHEA(S) synthesis.<sup>6,7</sup> The decline in  $\Delta$ -5 androgens and the parallel increase in cortisol/DHEA(S) ratio has been reported to be in part responsible for the physiological and/or pathophysiological age-related changes.<sup>8,9</sup>

It can be suggested that the decline of circulating androgens results from a combination of two events: ovarian failure plus age-related decline in adrenal androgen synthesis. The relative androgen deficiency in post-menopausal women may provoke an impairment in sexual function, wellbeing, and energy, and may contribute to bone mass reduction. However, the decline in circulating T, A, and DHEA levels begins in the decades that precede the menopause and sometimes the aforementioned symptoms can be detected in the peri-menopausal years as a consequence of the so-called adrenopause. In fact, as the menopause is characterized by a decline in gonadal function, adrenopause is characterized by the age-related reduction of the  $\Delta$ -5 adrenal pathway.

### Androgens and the Brain—Local Action and Metabolism

There is an increasing amount of data supporting the biological basis for androgens as neuroprotectants or neuromodulators during brain development but also during brain aging, and also the importance of androgens on the systems involved in cognitive function, mood disturbances, and central drive of sexuality.<sup>10,11</sup>

One of the complexities in understanding the effects of androgens is that these steroids have a very broad spectrum of activity, acting *per se* on



Nicola Pluchino, MD, is a Gynecologist in the Department of Reproductive Medicine and Child Development at the University of Pisa. He is also Deputy Assistant in the Neuroendocrinology of Reproduction Unit and the Gynecological Endocrinology and Menopause Center at the University of Pisa. Dr Pluchino is a member of the Endocrine Society, the International Society of Gynecological Endocrinology (ISGE), and the Society of Gynecological Investigation (SGI). He is the author of more than 40 papers in peer-reviewed journals on reproductive medicine, neuroendocrinology, sexual medicine, and menopause.



Andrea Riccardo Genazzani, MD, PhD, FRCOG, is Director of the Department of Obstetrics and Gynecology at the University of Pisa. He is also President of the International Society of Gynecological Endocrinology (ISGE) and the European Society for Gynaecologic and Obstetric Investigation (ESGOI), and Past President of the International Menopause Society (IMS). He was a member of the Scientific and Ethical Review Group of the World Health Organization (WHO) special program in Research, Development, and Training in Human Reproduction between 1998 and 2002. Dr Genazzani has authored more than 537 papers in peer-reviewed journals.

E: a.genazzani@obgyn.med.unipi.it

nuclear receptors or throughout the metabolism into several neuroactive compounds. Androgen nuclear receptors are prominent in the hypothalamus, hippocampus, amygdala, and pre-frontal cortex—areas that are essential for learning and memory.<sup>12</sup>

These brain areas represent targets for androgens during the 'organizational/developmental' phase, mainly in the fetal–neonatal period when estrogens and aromatizable androgens modulate neuronal development and the formation of neuronal circuits, but they are the same brain regions that show functional loss with aging.

It has been demonstrated that neurons and glia express enzymes able to convert testosterone to estradiol and several 5 $\alpha$ -reduced androgens.<sup>13</sup> Furthermore, metabolism of dihydrotestosterone (DHT) results in the formation of 5 $\alpha$ -androstane-3 $\alpha$ ,17 $\beta$ -diol (3 $\alpha$ A-diol) as well as its 3 $\beta$ -isomer (3 $\beta$ A-diol), both of which are capable of eliciting estrogen-receptor-dependent responses.<sup>14</sup> 3 $\alpha$ A-Diol also acts like the analogous metabolites of progesterone and corticosterone to enhance gamma-aminobutyric acid (GABA)-benzodiazepine-regulated chloride channel function.<sup>15</sup> DHEA may also exert its effect by acting as a substrate for brain intracrine conversion to testosterone and DHT in androgen target tissues.<sup>16</sup> DHEA and its principal circulating metabolite, DHEA sulfate, have been demonstrated to exert a wide range of direct effects on neuronal function.<sup>17</sup>

It is of great relevance to remember that DHEA and DHEAS are also considered to be 'neurosteroids' because they are produced in the CNS and they may directly affect central function(s). The concentration of DHEA in the CNS is five to 10 times greater than plasma levels, and experimental studies indicate that the mammalian brain contains steroid pre-cursors such as cholesterol and lipid derivatives.<sup>18,19</sup> The concentrations of DHEA in the rat brain remain unchanged for a long time after the removal of gonads and adrenals.

Experimental evidence suggests that the effects of DHEA and DHEAS on the CNS occur directly through specific binding to the GABA<sub>A</sub> receptor, thus blocking the GABA-induced chloride transport or current in

DHEA and its principal circulating metabolite, DHEA sulfate, have been demonstrated to exert a wide range of direct effects on neuronal function.

synaptoneuroosomes and neurons in a dose-dependent manner with an increase of the neuronal excitability.<sup>20</sup> Moreover, a potentiating effect of DHEA on N-methyl-D-aspartate (NMDA) and sigma receptors has been reported in the rat brain.<sup>21</sup>

In addition, it has been demonstrated that chronic administration of DHEA in ovariectomized rats induces an increase of other neurosteroids not directly correlated with its metabolism, such as allopregnanolone, a GABA<sub>A</sub>

agonist steroid. This increase has been evaluated in brain areas such as the hippocampus and hypothalamus and pituitary gland and in serum.<sup>22</sup>

In experimental animals, DHEA treatment induced a memory-enhancing effect; *in vitro* studies suggest a neurotrophic effect on neurons and glial cells.<sup>23</sup>

Beta-endorphin is the endogenous opiate that has received the most research attention. It is also involved in emotional regulation, pain mechanisms, and the reward system.

T administration to ovariectomized rats exerts a powerful effect on the endogenous endorphin system: it enhances beta-endorphin (beta-END) levels not only at the hypothalamic level but also in several supra-hypothalamic structures, affecting the activity of endorphinergic neurones in the hippocampus, as well as in the frontal and parietal lobes. In contrast, the endorphin content of these supra-hypothalamic structures was not affected in male rats by orchidectomy or by any steroid replacement treatments.<sup>28</sup> These results suggest that cerebral structures receiving the endorphinergic peptide exhibit a sex-based difference in opioid-system sensitivity to gonadal hormones.<sup>29</sup>

Beta-END is the endogenous opiate that has received the most research attention. It is also involved in emotional regulation, pain mechanisms, and the reward system. In addition, it has been postulated that beta-END may play a major role in the mechanism of sexual arousal and pleasure in both sexes.<sup>30</sup> In both female and male rats, the administration of DHT for two weeks did not induce any changes in brain or plasma levels of beta-END, suggesting that the reduction of T to DHT by 5 $\alpha$ -reductase is not involved in the mechanism of action underlying T modulation of central opioid activity. The increase in beta-END content following estradiol administration to both female and male rats suggests that the aromatization of T is most likely the main mechanism of action by which  $\Delta$ -4 androgen treatment induces an increase in endogenous endorphins. While this result supports previous studies investigating the role of endogenous androgens in the modulation of male rat hypothalamic proopiomelanocortin (POMC) content,<sup>31</sup> our recent data suggest that aromatase activity may be crucial for steroid modulation of endorphin levels also in females.

The removal of testes in rats and monkeys reduces the density of synaptic contacts on dendrites spines of cornu ammonis 1 (CA1) pyramidal neurons. This effect is rapidly reversed following treatment with either testosterone or the non-aromatizable androgen DHT, suggesting that maintenance of normal synaptic density is androgen-dependent via a mechanism that does not require intermediate estrogen biosynthesis. Similar effects of these androgens are observed in ovariectomized female rats, except that in the female the actions of testosterone include a substantial contribution from estrogen formation. The ability to stimulate hippocampal spine synapse density is not directly related to systemic androgenic potency; thus, weak androgens such as dehydro-

epiandrosterone can stimulate hippocampal spine density to an extent comparable to that of DHT. In addition, it has been demonstrated that testosterone deprivation increases central levels of beta-amyloid and this protein dramatically decreases when a testosterone or DHT treatment is initiated. Furthermore, cognitive tests are deeply impaired after gonadectomy in rat models, while a fine performance is restored following administration of testosterone and two of its metabolites, DHT and 3-alpha androstenediol.<sup>24</sup>

DHEA administration at 50mg/day induced an improvement in psychological and physical wellbeing in post-menopausal women.

## Neuroendocrine Effects of Dehydroepiandrosterone

Few studies have been conducted in humans to investigate the physiological function of DHEA(S) and the possible role of this molecule on the CNS. DHEA administration at 50mg/day induced an improvement in psychological and physical wellbeing in post-menopausal women.<sup>8</sup> Recently, it has been shown that the oral administration of DHEA 50mg/daily tends to improve wellbeing and mood only in women.<sup>25</sup> Moreover, short-term treatment with DHEA(S)

(30–90mg/day for four weeks) in middle-aged and elderly patients results in an antidepressant effect.<sup>26</sup>

Long-term treatment with lower doses of DHEA (25mg for 12 months) significantly increased levels of DHEA, DHEAS, androstenedione, testosterone, DHT, estrone, estradiol, progesterone, 17 OH-progesterone, allopregnanolone, beta-END, and GH up to those observed in fertile women. In contrast, cortisol and gonadotropin levels progressively decreased in all groups. In particular, during the treatment period all adrenal androgens and progestins showed a significant increase in their response to ACTH, while the cortisol response decreased significantly. The results suggest a significant DHEA-induced change in adrenal enzymatic activities, as also evidenced by the change in precursor/product ratios during therapy, suggesting age-related changes in adrenal function.<sup>27</sup>

## Conclusion

Androgens play a primary role in female physiopathology. The age-related decline in the production of ovarian and adrenal androgens may significantly affect a woman's health and wellbeing. Androgen replacement therapy should be first-choice treatment, especially in younger women with either premature ovarian or surgically induced menopause suffering from a loss of wellbeing, fatigue, or libido that is not modified by estrogenic therapy.

Among androgens,  $\Delta$ -5 androgens such as DHEA(S) should be considered as an alternative choice to treat the androgen deficiency syndrome and/or symptomatic post-menopausal women. ■

- Zumoff B, Walter L, Rosenfeld RS, et al., Sex differences in the 24-hour mean plasma concentrations of dehydroisoandrosterone (DHA) and dehydroisoandrosterone sulfate (DHAS) and the DHA to DHAS ratio in normal adult, *J Clin Endocrinol Metab*, 1980;51:331–4.
- Longscope C, Franz C, Morello C, et al., Steroid and gonadotropin levels in women during the peri-menopausal years, *Maturitas*, 1986;8:189–96.
- Rannevik G, Jeppsson S, Johnell O. A longitudinal study of the perimenopausal transition. altered profiles of steroid and pituitary hormones, SHBG and bone mineral density, *Maturitas*, 1995;21:103.
- Burger HG, Dudley EC, Hopper DL, The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample, *J Clin Endocrinol Metab*, 1995;80:3537–45.
- Simon JA, Estrogen replacement therapy: effects on the endogenous androgen milieu, *Fertil Steril*, 2002;77(Suppl. 4): S77–82.
- Liu CH, Laughlin GA, Fischer UG, Yen SSC, Marked attenuation of ultradian and circadian rhythms of dehydroepiandrosterone in postmenopausal women: evidence for a reduced 17,20 desmolase enzymatic activity, *J Clin Endocrinol Metab*, 1990;71:900.
- Couch RM, Muller J, Winter JS, Regulation of the activities of 17-hydroxylase and 17,20-desmolase in the human adrenal cortex: kinetic analysis and inhibition by endogenous steroids, *J Clin Endocrinol Metab*, 1986;63(3):613–18.
- Mortola JF, Yen SS, The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in post-menopausal women, *J Clin Endocrinol Metab*, 1990;71:696–704.
- Morales AJ, Nolan JJ, Nelson JC, Yen SSC, Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age, *J Clin Endocrinol Metab*, 1994;78:1360.
- Janowsky JS, The role of androgens in cognition and brain aging in men, *Neuroscience*, 2006;138(3):1015–20.
- MacLusky NJ, Hajszan T, Prange-Kiel J, Leranth C, Androgen modulation of hippocampal synaptic plasticity, *Neuroscience*, 2006;138(3):957–65.
- Patchev VK, Schroeder J, Goetz F, Rohde W, Patchev AV, Neurotropic action of androgens: principles, mechanisms and novel targets, *Exp Gerontol*, 2004;39(11–12):1651–60.
- Martini L, Melcangi RC, Maggi R, Androgen and progesterone metabolism in the central and peripheral nervous system, *J Steroid Biochem Mol Biol*, 1993;47:195–205.
- Pak TR, Chung WC, Lund TD, et al., The androgen metabolite, 5alpha-androstane-3beta, 17beta-diol, is a potent modulator of estrogen receptor-beta1-mediated gene transcription in neuronal cells, *Endocrinology*, 2005;146:147–55.
- Frye CA, Van Keuren KR, Erskine MS, Related Articles, Behavioral effects of 3 alpha-androstenediol. I: Modulation of sexual receptivity and promotion of GABA-stimulated chloride flux, *Behav Brain Res*, 1996;79:109–18.
- Labrie F, Luu-The V, Labrie C, et al., Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone, *Endocr Rev*, 2003;24:152–82.
- Sullivan SD, Moenter SM, Neurosteroids alter gamma-aminobutyric acid postsynaptic currents in gonadotropin-releasing hormone neurons: a possible mechanism for direct steroid control, *Endocrinology*, 2003;144:4366–75.
- Majewska MD, Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance, *Prog Neurobiol*, 1992;38:379–95.
- Corpechot C, Young J, Calvel M, et al., Neurosteroids: 3 alpha-hydroxy-5 alpha-pregnan-20-one and its precursors in the brain, plasma, and steroidogenic glands of male and female rats, *Endocrinology*, 1993;133:1003–9.
- Majewska MD, Demigoren S, Spivak CE, The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor, *Brain Res*, 1990;526(1):143–6.
- Mellon SH, Griffin LD, Neurosteroids: biochemistry and clinical significance, *Trends Endocrinol Metab*, 2002;13:35–43.
- Bernardi F, Casarosa E, Pluchino N, et al., Effect of dehydroepiandrosterone on central and peripheral levels of allopregnanolone and beta-endorphin, *Fertil Steril*, 2005;83(Suppl. 1):1161–8.
- Vallee M, Mayo W, Le Moal M, Role of pregnenolone, dehydroepiandrosterone and their sulfate esters on learning and memory in cognitive aging, *Brain Res Brain Res Rev*, 2001;37(1–3):301–12.
- Edinger KL, Frye CA, Testosterone's analgesic, anxiolytic, and cognitive-enhancing effects may be due in part to actions of its 5alpha-reduced metabolites in the hippocampus, *Behav Neurosci*, 2004;118:1352–64.
- Wolf OT, Neumann O, Helhammer DH, et al., Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men, *J Clin Endocrinol Metab*, 1997;82:2363–7.
- Wolkowitz OM, Reus VI, Roberts E, Manfredi F, Chan T, Raum WJ, Ormiston S, et al. Dehydroepiandrosterone (DHEA) treatment of depression, *Biol Psychiatry*, 1997;41: 311–18.
- Genazzani AR, Pluchino N, Begliuomini S, et al., Long-term low-dose oral administration of dehydroepiandrosterone modulates adrenal response to adrenocorticotropic hormone in early and late postmenopausal women, *Gynecol Endocrinol*, 2006;22:627–35.
- Pluchino N, Ninni F, Casarosa E, et al., Sex differences in brain and plasma beta-endorphin content following testosterone, dihydrotestosterone and oestradiol administration in gonadectomised rats, *Neuroendocrinology*, 2008; in press.
- MacMillan SJ, Mark MA, Duggan AW, The release of beta-END and the neuropeptide-receptor mismatch in the brain, *Brain Res*, 1998;794:127–36.
- Argiolas A, Neuropeptides and sexual behaviour, *Neurosci Biobehav Rev*, 1999;23:1127–42.
- Chowen JA, Argente J, Vician L, et al., Pro-opiomelanocortin messenger RNA in hypothalamic neurons is increased by testosterone through aromatization to estradiol, *Neuroendocrinology*, 1990;52:581–8.



**WE ARE COMMITTED.**

The American Society for Reproductive Medicine is committed to supporting and sponsoring educational activities for the lay public and continuing medical education activities for professionals who are engaged in the practice of and research related to reproductive medicine. ASRM strives to be the nationally and internationally recognized leader in providing multidisciplinary information, education, advocacy, and standards in the field of reproductive medicine.

ASRM is headquartered in Birmingham, Alabama, and staffs an office in Washington, D.C., that works with elected government leaders on behalf of our advocacy efforts. For more information on the American Society for Reproductive Medicine and our efforts to promote reproductive health, visit our website at [www.asrm.org](http://www.asrm.org).



**AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE**  
1209 Montgomery Highway • Birmingham, AL 35216  
Tel (205) 978-5000 • Fax (205) 978-5005 • Email [asrm@asrm.org](mailto:asrm@asrm.org)

